Shukra Pharmaceuticals Financial Statements
Shukra Pharmaceuticals financial statements. In FY2026, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹7 Cr, net profit ₹-2 Cr and EPS ₹-0.04, with a net profit margin of -28.6% and ROE of -2.2%. Full financial statements from FY2024 to FY2026 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse SHUKRAPHAR FII DII holdings to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SHUKRAPHAR Revenue, Net Profit & EBITDA — Year-on-Year Growth
SHUKRAPHAR YoY (Mar 2025 vs Mar 2026) — revenue -53.3%, net profit -140.0%, EBITDA -77.8%. For live price, earnings ratios and company overview, see Shukra Pharmaceuticals share price today.
SHUKRAPHAR Income Statement — Revenue, EBITDA & Net Profit
Shukra Pharmaceuticals revenue ₹7 Cr, EBITDA ₹2 Cr, net profit ₹-2 Cr, EPS ₹-0.04 (2026) — net profit margin -28.6%. Read SHUKRAPHAR dividend history for the complete payout history and dividend yield track record.
| Particulars | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 7 | 24 | 8 | 15 | 7 | 40 | 12 |
| Expenses | 6 | 4 | 6 | 6 | 4 | 12 | 7 |
| EBITDA | 2 | 20 | 1 | 9 | 2 | 28 | 5 |
| Operating Profit Margin % | 11.00% | 81.00% | -7.00% | 55.00% | 24.00% | 69.00% | 37.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 18 | 0 | 8 | 1 | 27 | 4 |
| Tax | 2 | 5 | -2 | 2 | 0 | 7 | 1 |
| Net Profit | -2 | 13 | 2 | 5 | 1 | 20 | 3 |
| Earnings Per Share (₹) | -0.04 | 0.30 | 0.05 | 0.12 | 0.02 | 0.47 | 0.72 |
SHUKRAPHAR Balance Sheet — Assets, Liabilities & Shareholders' Equity
SHUKRAPHAR total assets ₹117 Cr, total equity ₹90 Cr, total liabilities ₹ Cr (2026) — ROE -2.2%.
| Particulars | 2026 | 2025 |
|---|---|---|
| ASSETS | ||
| Total Assets | 117 | 87 |
| Current Assets | 84 | 65 |
| Fixed Assets | 22 | 19 |
| Capital Work in Progress | 12 | 2 |
| Investments | 0 | 0 |
| Other Assets | 84 | 65 |
| LIABILITIES | ||
| Total Liabilities | ||
| Current Liabilities | 5 | 7 |
| Non-Current Liabilities | ||
| SHAREHOLDERS' EQUITY | ||
| Total Equity | 90 | 63 |
| Share Capital | 44 | 44 |
| Reserves & Surplus | 41 | 19 |
SHUKRAPHAR Cash Flow Statement — Operating, Investing & Financing
Shukra Pharmaceuticals operating cash flow ₹3 Cr, investing ₹-14 Cr, financing ₹5 Cr, net cash flow ₹-6 Cr (2026).
| Particulars | March 2026 | March 2025 |
|---|---|---|
| Operating Activities | 3 | 8 |
| Investing Activities | -14 | -1 |
| Financing Activities | 5 | -5 |
| Net Cash Flow | -6 | 2 |